Recurrent Gastrointestinal Carcinoid Tumor Recruiting Phase 2 Trials for Regorafenib (DB08896)

IndicationStatusPhase
DBCOND0028801 (Recurrent Gastrointestinal Carcinoid Tumor)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02259725Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsTreatment